(19)
(11)EP 0 004 059 A2

(12)EUROPEAN PATENT APPLICATION

(43)Date of publication:
19.09.1979 Bulletin 1979/19

(21)Application number: 79100661.2

(22)Date of filing:  06.03.1979
(51)International Patent Classification (IPC)2C07D 233/38, A61K 31/415
(84)Designated Contracting States:
BE CH DE FR GB IT LU NL SE

(30)Priority: 06.03.1978 US 884074

(71)Applicants:
  • Case Western Reserve University
    Cleveland Ohio 44106 (US)
  • NORTHWESTERN UNIVERSITY
    Evanston Illinois 60201 (US)

(72)Inventors:
  • Webster, Leslie T. c/o School of Medicine
    Cleveland, Ohio 44106 (US)
  • Warren, Kenneth S.
    New York New York 10036 (US)

(74)Representative: Werner, Hans-Karsten, Dr.Dipl.-Chem. et al
Patentanwälte Von Kreisler-Selting-Werner Postfach 10 22 41
50462 Köln
50462 Köln (DE)


(56)References cited: : 
  
      


    (54)Synthesis of 1-(thiocarbamoyl)-2-imidazolidinone and immunosuppressive compositions containing it


    (57) An immunosuppressive composition of matter comprising a pharmacologically acceptable diluent and an immunosuppressive effective amount of synthetically produced 1-(thiocarbamoyl)-2-imidazolidinone of the formula

    the method of suppressing an immunological response in a patient by administering an immunosuppressive effective amount of synthetically produced 1-(thiocarbamoyl)-2-imidazolidinone and a process for preparing 1-(thiocarbamoyl)-2-imidazolidinone.


    Description


    [0001] The present invention relates to the production of a new composition of matter of high immunosuppressive activity.

    [0002] The compound 1-(thiocarbamoyl)-2-imidazolidinone of the formula

    /synthesized in Helv. Chem. Acta Vol. 49 (1966) pages 2443-6 is disclosed as an intermediate in making other, structurally remote compounds of niridazole-like activity against schistosoma, parasites which enter the blood streams and debilitate millions of people in Asia and Africa. Niridazole, i.e./-(5-nitro-2-thiazolyl)-2-imidazolid-; inone, is the treatment of choice.

    [0003] It has now been found that this 1-(thiocarLamoyl)-2-imidazolinone intermediate is markedly active in suppressing immune responses such as might be encountered in tissue grafts, and the like.

    [0004] The product can be prepared chemically according to the following reaction scheme:



    [0005] The starting materials react in a one-to-one stoichiometry but advantageously thiourea is employed in excess, e.g. at least about six times the stoichiometric amount, to minimize substitution at the second free thioamide nitrogen. The reactions can be effected in water, water-miscible solvents such as lower alkanols, acetone or dioxane, or water-immiscible solvents such as benzene or other hydrocarbons, chlorobenzene and the like. The reaction temperature can be up to the boiling point of the solvent, if present, preferably at about 20 to 70°C. Ring closure can be effected with the aid of an alkaline acid-binding agent, e.g. alkali metal or ammonium hydroxide or carbonates or tertiary amines such as pyridine, trimethylamine, triethylamine, and the like. The by-product salt which forms is water-soluble and in that manner can be separated from the desired product which can then be recrystallized from ethanol.

    [0006] An illustrative process for the preparation of the active material synthetically is shown in the following example:

    EXAMPLE 1



    [0007] To a solution of 19.0 g (250 nmol) of thiourea in 400 ml of acetone, containing 12.5 g (90 mmol) of anhydrous potassium carbonate, which was heated to 50°C, was added drupwise with stirring over a 90 minute period, a solution of 5.0 g (47.4 mmol) of 2-chlnrocthyl isouyanate diluted in 150 ml of acetone. The reaction mixture was stirred for two more hours at 50°C. After the insoluble carbonate was removed by filtration, the solution was evaporated to dryness at 45°C under reduced pressure. The solids which remained were dissolved in 375 ml of N,N- dimethylformamide and heated to 94°C. Fourteen grams of sodium acetate trihydrate were added in one lot and the mixture stirred for 30 minutes at 94°C. After the solution had cooled to 45°C, the solvent was remuved by rotary evaporation.

    [0008] The solids were dissolved in 100 ml of water. Upon standing at 4°C, 1.8 g of crystals were deposited which contained approximately 90% by weight of a product,[which cochromatographcd with the product from Example 3, when subjected to analytical high pressure liquid chromatography as in Example 3.]

    [0009] Recrystallization from 60 ml of water gave 1.44 g of white crystals which melted at 203.5 to 205.5°C (uncorrected) and which was substantially free of thiourea. Traces of the starting material were removed by chromatography of the product in 250 mg lots on a Sephadex L11-20 (5 X 60 cm) which was developed with water. Under these conditions, thiourea eluted after about one bed volume of solvent had passed through, whereas the major product eluted after about two bed volumes.

    [0010] Finally, highly purified product (~99% by weight) was obtained in milligram quantities by preparative high pressure liquid chromatography, using water as the solvent, as follows:

    A µBondapak C18 column was washed with 10 column volumes of acetonitrile (Burdick-Jackson, uv-quality solvent) and then equilibrated with water which was highly purified by passage through a Milli-Q system (Millipore Corporation). When chromatography was done in water at a flow rate of 4.0 ml/minute, the active material eluted with a retention time of 21.6 minute. Again the column effluent was monitored at 256 nm and at the appropriate time, active material was collected.. The volume of the collected effluent was reduced to 4 ml by rotary evaporation at 30°C. Product was recovered as fine white powder after lyophilization.



    [0011] - When foreign tissues enter a human body, the body's immune system produces a "migration inhibitory factor" (MIF) to reject such tissues. Agents which block or prevent the production of MIF are termed "immunosuppressive agents" and are effective in reducing allergic and rejection responses as in organ and tissue transplants.

    [0012] The active material synthesized hereinabove exhibits such activity which can be demonstrated clearly with laboratory animals, e.g. by an assay procedure such as that described by David and David at page 249 of their "In Vitro Methods in Cell-Mediated Immunity" edited by Bloom et al (Academic Press, 1971),. A capillary tube technique with modified Mackaness chambers is employed to measure the MIF activity resulting from the addition of various levels of OCB-BGG and get to peritoneal exudate cells (PEC) obtained from Hartley guinea pigs sensitized to this antigen. The culture medium is Eagle's Minimal Essential Medium with penicillin (100 units/ml) and streptomycin (100 µg/ml), and is made to contain 15% normal guinea pig serum. Chambers are incubated for 24 hours at 37°C. Areas of migration are projected, traced, and quantitated by planimetry, MIF production'being ; expressed as percent inhibition of migration, calculated as:



    [0013] Twenty percent or greater inhibition of migration usually represents significant MIF production by this assay according to the Student's t test.

    [0014] More specifically, the compound of the invention, 1-(thiocarbamoyl)-2-imidazolidinone, at 100 ng./ml., significantly inhibits (p≤.O1) macrophage migration inhibitory factor (MMIF), which is produced by incubation of sensitized guinea pig lymphocytes in the presence of 125 units/ml. of PPD (purified protein derivative) as antigen. [The measurement of inhibition of MMIF to determine immuno-suppressant activity is described by Bloom et al., Science 153, 80-82 (1966); David et al., J. Immunol. 93, 264-273 (1964); George et al., Proc. Soc. Exp. Biol. Med. 111, 514-521 (1962); and Kreici et al., Immunology 16, 677-684 (1969)].

    [0015] As shown by the data presented in Table 1 below, using the Jerne-plaque assay described by Jerne et al., Cell Bound Antibody (Amos and Koprowski, eds.), pages 109-125, Wistar Institute Press, Philadelphia (1963), l-(thiocarbamoyl)-2-imidazolidinone, identified as "Cpd.", was found to suppress IgM antibody (immunoglob lin M, 19S) at concentrations from 0.01 to 0.1 mg./kg. against sheep red blood cells as antigen when administered orally to mice for three days. For purposes of comparison, data are also included for the known immunoregulator, Tilorone, 2,7-bis-[2-(diethylamino)ethoxy]fluoren-9-one, identified as "Ref.". Results are expressed in terms of the Immunomodulation Index, which is the ratio of the PFC/106 Lymphocyte count for the test compound at a particular dose vs. control, a ratio greater than unity indicating immuno- enhancement and a ratio less than unity indicating immunosuppression.

    [0016] 



    [0017] As shown by the data presented in Table 2 below, using the Jerne-plaquc assay described above, 1-(thiocarbamoyl)-2-imidazolidinone was found to enhance IgM antibody in Nu/Nu (i.e. athymic) mice at a dose of 0.1 mg./kg. (p.o.) administered in 11 daily doses beginning 7 days preceding antigen administration (sheep red blood cells) and continuing for 4 days thereafter. As before, for comparative purposes data are also given for Tilorone, and in addition the PFC/106 Lymphocyte count and the Immunomodulation Index calculated therefrom is given for heterozygous mice (Het.) which are the parents, having fully active thymi, of the athymic mice used to assess the test compounds.

    [0018] 




    Claims

    1. An immunosuppressive composition of matter comprising a pharmacologically acceptable diluent and an immunosuppressive effective amount of synthetically produced 1-(thiocarbamoyl)-2-imidazolidinone of the formula


     
    2. A method of suppressing an immunological response in a patient which comprises administering to such patient an immunosuppressive effective amount of synthetically produced 1-(thiocarbamoyl)-2-imidazolidinone of the formula


     
    3. A process for preparing 1-(thiocarbamoyl)-2-imidazolidinone comprising reacting thiourea with β-chlorethyl- isocyanate and then with an acid binding agent.